Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Share-based Compensation (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Share-based Compensation for 6 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 11.69% year-over-year to $7.6 million, compared with a TTM value of $33.8 million through Dec 2025, up 10.52%, and an annual FY2025 reading of $33.8 million, up 10.52% over the prior year.
  • Share-based Compensation was $7.6 million for Q4 2025 at Treace Medical Concepts, down from $8.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.6 million in Q2 2025 and bottomed at $402000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $4.8 million, with a median of $4.4 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 911.28% in 2021, then decreased 27.52% in 2022.
  • Year by year, Share-based Compensation stood at $3.4 million in 2021, then decreased by 27.52% to $2.5 million in 2022, then soared by 137.73% to $5.9 million in 2023, then soared by 45.69% to $8.6 million in 2024, then dropped by 11.69% to $7.6 million in 2025.
  • Business Quant data shows Share-based Compensation for TMCI at $7.6 million in Q4 2025, $8.0 million in Q3 2025, and $9.6 million in Q2 2025.